Comparing tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase when imatinib loses patent exclusivity in the u.s.- a cost-effectiveness analysis
Abstract
Authors
W. Padula R. Larson R. Conti S. Dusetzina